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for	 patients	with	 chronic	 inflammatory	 respiratory	 diseases,	 fulfilling	 the	 needs	 of	
2  |     FOKKENS Et al.
1  | INTRODUC TION
Chronic	 rhinosinusitis	 (CRS)	 is	 a	 chronic	 inflammatory	 condition	 of	
the	sinonasal	cavities	that	affects	5%-12%	of	the	general	population	
worldwide	 according	 to	 epidemiological	 studies.1-4	 The	 European	










(N-ERD),9	 smoking,	 age	 of	 onset,	 and	 disease	 severity.10-12	 Asthma	















The	 cornerstone	 of	 the	 management	 of	 both	 CRSwNP	 and	
asthma	 consists	 of	 anti-inflammatory	 treatment	 with	 local	 corti-
costeroids,	aiming	to	achieve	optimal	disease	control.5,21,22	When	
this	 is	 insufficient,	 short	 courses	of	oral	 corticosteroids	 are	used	
(usually	30-60	mg	for	14	days,	sometimes	reducing	over	time).23,24 
Sinus	surgery	is	the	treatment	option	for	CRSwNP	patients	in	cases	




focusing	on	 therapy	 targeted	 to	a	patient's	 individual	disease-as-






other	 monoclonal	 antibodies	 targeting	 type	 2	 inflammation	 36 
have	been	approved	and	are	available	now	for	patients	with	eo-
sinophilic	asthma,37-41	atopic	dermatitis,42,43	and	urticaria.36,42-46 




The	 European	 Forum	 for	 Research	 and	 Education	 in	 Allergy	
and	 Airway	 Diseases	 organized	 a	 multidisciplinary	 Expert	 Board	
Meeting	on	November	29-30,	2018,	to	develop	proposals	for	the	
positioning	 of	 biologics	 into	 the	 care	 pathways	 for	 CRSwNP	 pa-
tients	 with	 or	 without	 asthma.	 Subsequently,	 a	 patient	 advisory	
board	 meeting	 was	 held	 to	 discuss	 the	 outcomes	 of	 the	 Expert	
Board	Meeting.
severely	uncontrolled	patients.	The	majority	of	patients	with	chronic	 rhinosinusitis	
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2  | SE VERIT Y AND THE BURDEN OF 




loss	of	 sense	of	 smell	 is	a	debilitating	and	often	underappreciated	
component	and	can	significantly	impact	one’s	quality	of	life.56,57
The	 terms	 “disease	 control”	 and	 “disease	 severity”	 cannot	 be	
used	interchangeably.	In	CRSwNP,	severity	is	defined	by	the	impact	
of	the	symptoms	on	general	quality	of	life	and	it	can	be	measured	














measures	 of	 disease	 control.	 In	 clinical	 practice,	 systemic	 cortico-
steroids	are	used	more	frequently	and	for	longer	periods	than	pro-
posed	in	guidelines.8,60	Real-life	studies	are	needed	to	determine	the	




Symptomatic	 nasal	 polyp	 recurrence	 rates,	 defined	 as	patients	
undergoing	 revision	 endoscopic	 sinus	 surgery,	 are	 reported	 to	 be	
20%	within	a	5-year	period	after	surgery	62,63	but	may	be	as	high	as	
50%	on	endoscopic	examination.62
Type	 2	 disease	 is	 a	 strong	 predictor	 of	 recurrent	 disease	with	
more	 than	 50%	 of	 recurrences	 occurring	 in	 clusters	 with	 high	
eosinophilia.62-65
The	 Global	 Initiative	 for	 Asthma	 (GINA)	 suggests	 assessing	
asthma	severity	retrospectively	from	the	level	of	treatment	required	
to	control	symptoms	and	exacerbations.	Mild	asthma	is	asthma	that	
can	 be	 controlled	 with	 low-dose	 inhaled	 corticosteroids.	 Severe	
asthma	 is	 defined	 as	 asthma	 that	 requires	 treatment	 with	 high-
dose	 inhaled	 corticosteroids	 (ICS)	 plus	 a	 second	 controller	 and/or	
systemic	 corticosteroids	 to	maintain	 symptom	control	 (after	other	




airways	 in	 patients	with	CRS	 and	 asthma	 and	many	 patients	with	
severe	asthma	have	comorbid	CRSwNP,	which	should	be	addressed	
to	 optimize	 asthma	 control.67-69	 To	 conclude,	 the	management	 of	
CRSwNP	and	 asthma	patients	who	are	uncontrolled	despite	med-
ical	 and	often	 surgical	 intervention	 remains	a	 challenge.	However,	
in	 recent	 years,	 there	 has	 been	 significant	 innovation	 and	 expan-
sion	in	the	treatment	armamentarium	since	the	advent	of	biological	
therapies.
3  | EFFIC ACY OF BIOLOGIC AL 








countries,	 biologics	 are	 indicated	 in	 moderate-to-severe	 asthma	
with	insufficient	level	of	control	despite	high	dose	of	inhaled	corti-
costeroids	combined	with	at	least	one	other	asthma	medication	and	
where	 severe	 exacerbations	 and/or	 oral	 corticosteroid-dependent	
asthma	have	been	demonstrated.
The	 first	 proof-of-concept	 studies	 in	 CRSwNP	 using	 anti-IgE,	
anti-IL5,	 and	 anti-IL4Rα	 strategies	 also	 showed	 promising	 results	
and	have	been	 summarized	earlier.50,73	Recent	 larger	 scale	 studies	








F I G U R E  1   Indications	for	biological	treatment	in	patients	with	
CRSwNP:	proposal	of	the	multidisciplinary	EUFOREA	Expert	Board	
Meeting




4  | INDIC ATIONS FOR BIOLOGIC S
The	 high	 burden	 of	 uncontrolled	 disease,	 the	 recurrence	 of	 nasal	
polyps	 after	 sinus	 surgery,	 and	 the	 side	 effects	 associated	 with	
repeated	courses	of	oral	corticosteroids	all	underline	the	need	for	
novel	therapies.	Given	that	biologics	come	with	a	high	cost	for	the	
healthcare	 system,	 careful	 selection	 of	 patients	 is	 highly	 recom-











There	was	an	extensive	discussion	of	whether	 there	 is	a	 role	
for	biologics	 in	patients	without	previous	 sinus	 surgery.	 If	 these	
patients	 meet	 the	 criteria	 for	 severe	 asthma,	 they	 might	 ful-
fill	 the	 eligibility	 criteria	 to	 receive	biological	 treatment	 by	 their	
pulmonologist.















tients	with	grade	3	CRSwNP	and	asthma.49	 It	was	 concluded	 that	













General	 contraindications	 for	 biological	 treatments,	 such	 as	
immunodeficiencies
Patient-related	factors	such	as	noncompliance	to	therapy
5  | DEFINING RESPONSE TO BIOLOGIC S
Despite	significant	efficacy	of	biologics	on	various	clinical	and	pa-
tient-reported	 outcome	measures	 in	 the	 overall	 study	 population,	
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considerable	variability	in	the	degree	of	response	to	such	therapies	
is	seen.	These	observations	underpin	the	need	to	identify	treatment	



















6  | POSITIONING OF BIOLOGIC S IN 
THE CHRONIC RESPIR ATORY DISE A SE‐
INTEGR ATED C ARE PATHWAY
New	 developments	 in	 understanding	 pathophysiology	 and	 treat-
ment	 require	 new	 care	 pathways.	 Recently,	 integrated	 care	 path-





tice	 requires	both	collaboration	between	 first,	 second,	and	 third	
lines	 of	 care	 and	 across	 specialties	 (ENT,	 pulmonology,	 allergol-
ogy).	Patients	pointed	out	during	the	advisory	board	meeting	that	
awareness	about	CRS	and	nasal	polyps	and	best-practice	manage-







further	 development	 of	 disease	 and	 be	 highly	 cost-effective.	
Patients	with	 a	high-risk	phenotype	 (asthma	and	N-ERD)	 should	
be	referred	to	specialist	centers	early	in	their	disease	to	optimize	
multidisciplinary	management.
Many	 patients	will	 predominantly	 have	 upper	 or	 lower	 airway	
diseases.	However,	it	is	recommended	that	every	patient	with	CRS	
gets	at	least	one	systematic	evaluation	for	asthma	and	allergy	pref-
erably	 by	 a	 validated	 questionnaire	 and	 if	 at	 risk	 for	 asthma,	 spi-
rometry	to	assess	lung	function;	skin	prick	test	or	measurement	of	
specific	 blood	 IgE;	 and	 measurement	 of	 blood	 eosinophil	 counts.	
Similarly,	for	patients	with	asthma	it	is	recommended	that	every	pa-
tient	 is	 evaluated	 for	 upper	 airway	 problems	 (rhinitis	 or	 CRS)	 and	
allergy	 preferably	 by	 a	 validated	 questionnaire;	 nasal	 endoscopy,	
skin	prick	test,	or	measurement	of	specific	blood	IgE;	and	measure-
ment	of	blood	eosinophil	counts.	However,	a	subgroup	of	patients	
with	 severe	CRS	 and	 asthma	may	 benefit	 from	 an	 intensified	 col-
laboration	between	ENT	and	pulmonologist	and	where	appropriate	
allergologist.
Remarkably,	 only	 a	 few	 of	 the	 physicians	 in	 the	 Expert	 Board	




of	 both	 upper	 and	 lower	 airways	 at	 every	 visit;	 treatment	 adjust-
ments	with	 attention	 to	 the	 full	 unified	 airways;	 regular	measure-
ment	of	type	2	biomarkers;	and	monitoring	of	the	use	of	systemic	
corticosteroids.
7  | CONCLUSION AND UNMET RESE ARCH 
NEEDS
A	 multidisciplinary	 EUFOREA	 Expert	 Board	 Meeting	 and	 patient	
advisory	board	came	together	under	the	auspices	of	the	European	
Forum	for	Research	and	Education	in	Allergy	and	Airway	Diseases.	
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